Vertex Pharmaceuticals PRICE TARGET and 4 Analyst Alerts Ending the Week
Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) test of Vertex’s Kalydeco +VX-809 in cystic fibrosis patients indicated that the med failed to improve lung functioning by a statistically significant amount. Therefore, Piper remains confident that Vertex’s cystic fibrosis franchise represents a stellar opportunity, and restates its $75 price target and Overweight on the shares.
Mattress Firm Holding Corp (NASDAQ:MFRM) retains its Outperform at William Blair, after May wholesale data by the International Sleep Products Association showed that sales of mattresses and foundations increased by 18.3 percent in the month of May. The analyst firm thinks that shares offer an attractive value, and it maintains its Market Perform rating on Tempur-Pedic (NYSE:TPX).
HMS Holdings Corporation’s (NASDAQ:HMSY) ‘major overhang’ was removed by Thursday’s Supreme Court ruling which upheld the Affordable Care Act, says Dougherty, and that it also improves the firm’s outlook and visibility. Shares of HMS are rated Buy.
UniFirst Corp. (NYSE:UNF) posted third quarter figures that exceeded expectations, leading Barrington to believe that the company is executing well. On the other hand, the analyst opines that UniFirst is being held back by the “sluggish” economy, and it thus keeps its Market Perform on the shares.
Orbotech Ltd.’s (NASDAQ:ORBK) price target was lowered by JPMorgan subsequent to its second half of 2012 guidance, plus its higher expenditures because of its legal investigation in Korea. Shares are rated Neutral.